{'fraction_non_alphanumeric': 0.02656042496679947, 'fraction_numerical': 0.01859229747675963, 'mean_word_length': 5.180327868852459, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Open Label Assessment of Botulinum Toxin A for Pain Treatment in a Private Outpatient Setting

Objective: To determine efficacy and injection characteristics of botulinum toxin A [BTXA] treatment for refractory muscular pain in a private outpatient setting. Methods: Medical records were analyzed retrospectively for a sample 44-patient cohort who received BTXA injections for refractory muscular pain between 1/1/96 and 12/31/98. Results: Eighty percent of all patients reported reduced pain from the initial BTXA treatment. Thirty-two percent required one repeat injection and 27% received three or more. Conclusion: These data suggest that BTXA may reduce focal muscular pain, and in many cases, the benefit outlasts the expected action of the toxin.